Executive Director, Medical Evidence Generation Cell Therapy, Global Medical Affairs at Bristol-Myers Squibb

Lawrence Twp, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Leadership experience in medical evidence generation, particularly in cell therapy or oncology portfolios
Ability to develop and implement evidence generation plans, including Medical Affairs Sponsored studies, clinical research collaborations, investigator-sponsored studies, and health outcomes studies
Expertise in Integrated Evidence Plans (IEPs) development and maintenance
Strategic planning skills for 3-year MEG plans and portfolio oversight
Strong matrix leadership and collaboration across functions like Global Medical, International Medical, Research & Discovery, Global Drug Development (GDD), HEOR, GBDS, Regulatory, and Pharmacovigilance
Experience in scientific oversight, clinical decision-making, study conception, writing, monitoring, and execution
Fiscal responsibility in managing budgets for evidence generation book of work (BOW)
Ability to foster innovation, data-driven decision-making, and business savviness
Enterprise mindset for aligning on evidence gaps, reviewing proposals, and executing studies

Responsibilities

Lead the development and implementation of the evidence generation book of work for the Cell Therapy portfolio/pipeline
Oversee development of Integrated Evidence Plans (IEPs) aligned with unmet medical needs and business priorities
Develop the 3-year strategic MEG plan for Cell Therapy and provide oversight and thought partnership on trade-offs
Provide end-to-end medical oversight for Cell Therapy MEG portfolio (Medical Affairs sponsored studies, clinical research collaborations, investigator-sponsored studies)
Serve as matrix partner with CT Leadership Team, Global Medical, and International Medical teams; facilitate Medical governance through TAG forum and EGWG meetings
Foster innovative culture and leverage data analytics for evidence generation and value-driven decisions
Provide scientific oversight and clinical decision-making for studies, including conception, writing, monitoring, accrual, and completion
Ensure fiscal responsibility by maintaining a balanced budget for MEG Book of Work (BOW)
Chair Review Committees or contribute to approval processes for studies and collaborations

Skills

Key technologies and capabilities for this role

Medical Evidence GenerationIntegrated Evidence PlansCell TherapyInvestigator-Sponsored StudiesHealth EconomicsOutcomes ResearchStrategic LeadershipMatrix LeadershipClinical Research Collaborations

Questions & Answers

Common questions about this position

What benefits does Bristol Myers Squibb offer?

Bristol Myers Squibb offers a wide variety of competitive benefits, services, and programs that provide employees with resources to pursue their goals both at work and in their personal lives.

Is this a remote position or does it require office work?

This information is not specified in the job description.

What are the key responsibilities for this role?

The role involves leading the development and implementation of the evidence generation book of work for Cell Therapy, overseeing Integrated Evidence Plans (IEPs), and providing portfolio leadership for medical oversight of studies.

What is the company culture like at Bristol Myers Squibb?

The culture is challenging, meaningful, and life-changing, with uniquely interesting work, opportunities to grow alongside high-achieving teams, and emphasis on balance and flexibility.

What makes a strong candidate for this position?

A strong candidate will have strategic leadership experience, an enterprise mindset to lead across the BMS matrix, and the ability to collaborate with stakeholders from Global Medical, Research & Discovery, GDD, HEOR, and other functions.

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free